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Background: Compared to inhaled corticosteroids (ICS), better use of leukotriene-receptor
antagonists (LTRA) may lead to a greater reduction in exacerbations among asthmatic children
in real-life settings.
Methods: To test this hypothesis, we used the Quebec administrative databases and identified
a cohort of 27,355 asthmatic children aged 5e15 years in whom ICS or LTRA monotherapy was
initiated in 1998e2005. The primary outcome was the rate of moderate-or-severe asthma
exacerbations (emergency department visit or hospitalization for asthma or a dispensed
prescription of oral corticosteroids) over the subsequent year. The adjusted rate ratios (RR)
of asthma exacerbations were estimated with Poisson regression models. To minimize con-
founding by indication, all analyses were stratified by the presence or not of an asthma exac-
erbation in the year before treatment initiation. We also measured the proportion of days with
supply prescribed and patient’s adherence with the Proportion of Prescribed Days Covered
(PPDC).
Results: The risk of exacerbations was significantly higher in the ICS than the LTRA group
among children with no previous exacerbation (RR Z 2.3; 95%CI:1.3e4.0), but not in those
with 1 exacerbations (RR Z 1.6; 0.8e3.1). The PPDC was similar between the groups (66%)
but the proportion of days with supply prescribed was significantly higher in the LTRA than
the ICS group (52% vs. 34%), resulting in higher use.de Montre´al, Faculte´ de Pharmacie, C.P. 6128, Succursale Centre-ville, Montre´al, Que´bec,
1x3786; fax: þ1 514 343 6120.
real.ca (L. Blais).
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more frequently prescribed as an intermittent than a daily controller therapy resulting in less
use, which may contribute to the apparent lower effectiveness compared to LTRA.
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Regular daily therapy with inhaled corticosteroids (ICS) or
leukotriene-receptor antagonists (LTRA) is effective in
reducing asthma exacerbations in both adults and child-
ren.1e4 According to current guidelines on asthma
management and prevention, ICS remain, however, the
preferred controller monotherapy for persistent asthma.5e7
This recommendation is further supported by a 2004
Cochrane Review of 27 trials including adults and children
reporting a 65% higher risk of exacerbations requiring
systemic steroids in patients treated with LTRA compared
to ICS.8 Subsequent to this review, several recent
randomized clinical trials also demonstrated the superiority
of ICS over LTRA in children for a broad range of clinical
endpoints, including asthma control.9e12
Whether the superiority of ICS over LTRA persists in real
life practice remains to be proven. Indeed, the use of ICS is
notoriously low, frequently hovering around 45% of the time
when filled prescriptions are examined.13 Although the use
of LTRA is also not optimal, it generally appears superior to
that of ICS, being reported to be between 60 and 70%,13,14
perhaps because of its oral administration, which makes it
easier and more convenient to take than inhaled medica-
tions, particularly in children.15,16 Few observational
studies have compared the relative effectiveness of ICS and
LTRA in children,17,18 yielding conflicting results. While one
study concluded that users of LTRA were more likely to
experience treatment failure and to be admitted to the
hospital for asthma,17 the other reported no group differ-
ence in the rate of asthma-related resource use, hospital-
izations, or rescue medication use.18 None of these studies
compared the proportion of days with supply prescribed,
patient’s adherence to the prescribed therapy and the
usage of ICS and LTRA, which are important elements to
consider when examining drug effectiveness.
We undertook a population-based study to investigate
the relative effectiveness of ICS and LTRA for preventing
moderate and severe asthma exacerbations among asth-
matic children aged 5e15 years. We also aimed to explore
determinants of effectiveness, namely the proportion of
days with supply prescribed, adherence to, and use of the
therapy, and prior asthma severity. Our hypothesis was that
better adherence to LTRA than ICS would lead to a greater
reduction in the rate of moderate or severe asthma exac-
erbations among patients treated with LTRA.
Methods
Source of data
Data for this study were retrieved from two administrative
databases from the Canadian province of Que´bec: the Re´gie
de l’Assurance Maladie du Que´bec (RAMQ) and the MED-ECHO databases that are linked by a patient unique
encrypted identifier. The RAMQ provides medical coverage
to all Quebec residents and drug coverage to about 42% of
the population,19 including the elderly (65 years), persons
receiving social assistance, and workers and their families
(called the adherents) who do not have access to a private
drug insurance plan from their workplace. Children of
parents insured by the RAMQ Drug Insurance Plan are
automatically insured and prescribed medications are free
of charge for them. The RAMQ database includes three
types of files. The Beneficiary file gives information on
patients’ characteristics, such as age, sex, area of resi-
dence, social aid status and periods of coverage for the
medication insurance. The Medical Services file contains all
the information relative to medical services received e.g.
the type, date, and location of medical service (outpatient
clinic, emergency department (ED), hospitalization), diag-
nostic codes, as well as the specialty of the treating
physician. The Prescription Drugs file contains data on
prescribed medications dispensed in community pharma-
cies and includes notably the name of the medication,
dosage, amount of medication given to the patient, the
dispensing date, the type of prescription (new or refill),
the number of refills allowed with a new prescription, the
prescription duration, and the specialty of the prescribing
physician. The MED-ECHO database contains information on
all acute care hospitalizations occurring in the province,
e.g. the date of admission and length of stay as well as
primary and secondary diagnoses. These databases are
routinely used for epidemiological asthma research.20e24
Data recorded in the RAMQ Prescription Drugs file and the
medical diagnosis for asthma recorded in the RAMQ Medical
Services file have been formally evaluated and vali-
dated.25,26 This study has been approved by the Ethics
Committee of the Hoˆpital du Sacre´-Coeur de Montre´al.
Study design
From the RAMQ database, we reconstructed a cohort of
asthmatic children that initiated a treatment in mono-
therapy with either ICS [beclomethasone, fluticasone or
budesonide] or LTRA [montelukast or zafirlukast]. Patients
were eligible if they fulfilled the following inclusion
criteria: (1) first prescription of monotherapy with ICS or
LTRA between January 1st 1998 and August 31st, 2005;
(2) no prior asthma controller therapy, that is, no dispensed
ICS and LTRA prescriptions in the year preceding to the
treatment initiation; (3) at least one asthma diagnosis
(ICD-9 493) recorded in the RAMQ database in the year prior
to treatment initiation; (4) age between 5 and 15 years at
treatment initiation; (5) covered by the RAMQ Drug Insur-
ance Plan for at least one year prior to treatment initiation;
and (6) a follow-up of at least 4 months after treatment
initiation. Patients were excluded if they had at least one
diagnosis of chronic bronchitis, cystic fibrosis, dyspnea, or
848 L. Blais et al.laryngotracheitis or a dispensed medication to treat these
conditions in the year prior to treatment initiation. Patients
were excluded if they had regular therapy with oral corti-
costeroids in the year prior to treatment initiation (182
supply days or more) or in the first 3 months following
treatment initiation (45 supply days or more).
Patients were followed for a minimum of 4 months and
a maximum of 12 months after treatment initiation. A
minimum of 4 months of follow-up was required in order to
obtain a precise measure of adherence to ICS and LTRA.
Follow-up was terminated before the 12th month (i.e.
data were censored) if one of the following events
occurred: a dispensed prescription of another controller
therapy (i.e. a class switch or a class addition), end of drug
coverage by the RAMQ Drug Insurance Plan, 16th birthday,
or death. Data were obtained from the RAMQ between
January 1st, 1997 and December 31st, 2005. The cohort
selected from the RAMQ was then linked to the MED-ECHO
database with a unique patient identifier to obtain data on
acute care hospitalizations that occurred during the same
period.
Primary and secondary outcomes
The primary outcome was the rate of moderate or severe
asthma exacerbations defined as an emergency department
(ED) visit for asthma, a hospital admission for asthma, or
a dispensed short-course (14 days) prescription of oral
corticosteroids. All the aforementioned events occurring
during a 15-day interval were considered as a single exac-
erbation. The secondary outcome was a dispensed short-
course prescription of oral corticosteroids, a marker of
a moderate or severe asthma exacerbation27 more specific
than an acute care visit where as many as 50% could be
made for mild exacerbation.28
Compared therapy
Children with asthma initiating a treatment with ICS as
monotherapy were compared to those initiating a mono-
therapy with LTRA.
Confounding and stratification variables
Potential confounders measured in the year before treat-
ment initiation included average number of doses of
inhaled short-acting beta2-agonists (SABA) per week (3,
>3e10, >10), oral SABA (0, 1 filled prescription) and
inhaled long-acting beta2-agonists (LABA) (0, 1 filled
prescription). Potential confounders measured at treat-
ment initiation were age (5e11, 12e15 years), gender, child
living with parents receiving social assistance (yes/no),
area of residence (urban/rural), specialty of the prescribing
physician (family physician, paediatrician, respiratory
specialist, others), and initial daily dose prescribed. To
estimate the daily dose of ICS prescribed (expressed in
beclomethasone-equivalent doses), we developed an algo-
rithm based on the name of the medications and equiva-
lencies between the different ICS products as recognized by
the Canadian Asthma Consensus guidelines,29 the content
of active ingredient per dosage unit and the quantity ofdrug prescribed, the date and duration of the prescription,
and the rate of renewals of the prescription. A second
algorithm was developed in order to obtain an estimate of
the average number of inhaled SABA filled per week, based
on the name of the medications and equivalencies between
the different SABA agents, as established by a pharmacist
(M-F.B), date of filling, prescription renewals, and length of
time between renewals.30 The average number of doses per
week was divided into three categories (3, >3e10, >10
doses per week), according to the Canadian Asthma
Consensus guidelines.29
In order to minimize potential confounding by indication
due to the severity of asthma, we performed all analyses
stratified on the occurrence or not of a moderate or severe
asthma exacerbation in the year before treatment
initiation.
Prescription pattern, treatment adherence and
usage of medications
Prescription pattern was assessed by the proportion of days
with supply prescribed. This measure is obtained by
dividing the total days’ supply prescribed (i.e. the sum of
the duration of all prescriptionsdnew and allowed refills
from all physicians consulted during the follow-up period)
over the number of days of follow-up. Of note, the duration
of allowed refills were summed whether or not the patient
went to the pharmacy to get the refills.
Treatment adherence was measured by the “Proportion
of prescribed Days Covered” (PPDC), a new measure of
patient’s adherence that has been recently developed by
our group.31 The PPDC is defined as the total days’ supply
dispensed during the follow-up over the total days’ supply
prescribed.31
Finally, the usage of medications was summarized as the
“number of prescription dispensed” and “the proportion of
days covered” (PDC). The PDC is defined as the total
number of days with supply dispensed during the follow-up
over the number of days of follow-up.32 The PDC reflects
the behaviour of both the patient and the prescribing
physician and consequently the usage of medications, while
the PPDC tends to measure more specifically the behaviour
of the patient as it measures patient adherence to the
therapy that was actually prescribed, and not to the
therapy that should have been prescribed according to
clinical guidelines, i.e. chronic daily use in the case of ICS
and LTRA.
Statistical analysis
All analyses, including the description of patient charac-
teristics, were stratified by the presence or not of
a moderate or severe asthma exacerbation (as defined in
the primary outcome) in the year before treatment initia-
tion with ICS or LTRA. We calculated the crude rate (per
person per year) of moderate or severe asthma exacerba-
tions and use of short-course of oral corticosteroids during
follow-up, separately for patients treated with ICS and
LTRA. The crude and the adjusted rate ratios (RR) of the
outcomes, comparing patients treated with ICS to LTRA,
were calculated using Poisson regression models with
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intervals (CIs). All potential confounding variables were
entered in the models.33 We also calculated the mean
(standard deviation) proportion of days with supply
prescribed, PPDC, PDC and number of filled prescriptions of
ICS and LTRA and compared these measures between ICS
and LTRA patients using t-tests. All reported P-values are
two-sided, with a significance level of 0.05. All analyses
were performed using SAS software, version 9.1 (SAS Insti-
tute Inc., Cary, NC, USA).
Results
Patients’ characteristics
The cohort consisted of 27,355 children, including 7494
(27%) children with at least one exacerbation and 19,861
(73%) without any exacerbation in the year prior to treat-
ment initiation. A flow chart with the number of patients
excluded and the number of patients in which follow-up
was censored is available in the online supplement. For
note, among children who had suffered at least one
exacerbation in the year prior treatment initiation, 74%
experienced it in the 15 days preceding treatment
initiation.
Children’s characteristics are depicted in Table 1.
Within strata defined by the presence or not of previous
exacerbation, the two groups were comparable for socio-
demographic characteristics, but we observed differ-
ences in variables related to asthma. Among children who
had at least one exacerbation in the year preceding
treatment initiation, a greater proportion of children
treated with LTRA than ICS were prescribed their initial
controller medication by a paediatrician, had used high
doses of SABA, filled 2 prescriptions of oral corticoste-
roids, had made outpatient (non ED) visits for asthma,
and had 2 moderate or severe exacerbations in the year
prior to the initiation of the therapy. However, children
treated with ICS were more likely to have had an ED visit
and a hospitalization for asthma in the year prior to the
initiation of the therapy. Similar trends were observed
among children who had no exacerbation prior to treat-
ment initiation.
Among children who had at least one exacerbation in the
year prior to treatment initiation, the proportion of chil-
dren who received their initial prescription during an ED
visit (prescription filled at most 15 days after the ED visit)
was significantly higher in the ICS group than in the LTRA
group (55% vs. 13%; p < 0.0001). The median starting daily
dose of ICS prescribed was high (about 1000 mg/day),
whether children had had an asthma exacerbation or not in
the year before treatment initiation.
Crude rate of asthma exacerbations
In the strata with no exacerbation in the preceding year,
the crude rate of moderate to severe exacerbations, rescue
oral corticosteroids, and ED visits was significantly higher
among those treated with ICS than among those treated
with LTRA; no group difference was found in the other
strata (Table 2).Adjusted rates of asthma exacerbations
The adjusted rate ratios confirmed these above findings. In
the strata with no previous exacerbation, the risk of
exacerbations was two-fold higher in the ICS compared to
the LTRA groups (adjusted RR Z 2.3; 95% CI; 1.3e4.0)
(Table 3). A similar trend favouring LTRA but not reaching
statistical significance was observed in the other strata
(adjusted RR Z 1.6; 95% CI: 0.8e3.1). Comparable rate
ratios favouring LTRA were seen regarding the use of oral
corticosteroids in both strata, again statistically significant
RR Z 2.3; 1.2e4.6 only among children with no previous
exacerbation (RR Z 2.0; 0.8e5.3 among children with
previous exacerbation).
In both strata, an increased risk of asthma exacerbations
with ICS compared to LTRA was associated with prescrip-
tions by paediatricians at treatment initiation and with an
increased number of doses of inhaled SABA per week in the
year prior to treatment initiation. Oral SABA in the
preceding year was also associated with an increased risk of
exacerbations in the ICS group among children with
a history of asthma exacerbations.
Treatment adherence to ICS and LTRA in the year
following treatment initiation
There was no group difference in patients’ adherence
measured by the PPDC, which hovered around two-thirds
for both groups (Table 4). Yet, the mean PDC, that is the
proportion of days with a controller medication, was two-
fold higher in the LTRA group than the ICS group
(p < 0.001), in both strata. Similarly, the proportion of days
with supply prescribed and the number of prescriptions
filled were significantly higher among children treated with
LTRA than ICS.
Discussion
In this observational study among Canadian children with
asthma, initiation of monotherapy with ICS was associated
with a two-fold higher rate of exacerbations compared to
LTRA, but only among children with no exacerbation
requiring a health care utilisation in the year before
treatment initiation; there was no significant group differ-
ence among those with exacerbations in the preceding
year. In both strata, patients’ adherence rates were similar
between ICS and LTRA groups, hovering around two thirds
of the prescribed doses. However, there was two-fold
higher daily usage of LTRA than ICS, resulting from
a combination of a higher proportion of days with a supply
prescribed by the physician and a higher number of
prescription dispensed per year in the LTRA than the ICS
groups.
The observed relative risk of exacerbations in our study
contradicts those of previous randomized clinical trials
demonstrating better outcomes with ICS compared with
LTRA.912 The present investigation was based on data from
actual practice, resulting from a combination of the
physician prescription patterns and duration, and the
patient adherence to filling the prescribed medications.
While the results from clinical trials have high levels of
Table 1 Children’s Characteristics.
1 exacerbation in the
year prior to treatment
initiation
No exacerbation in the
year prior to treatment
initiation
ICSa LTRAb ICSa LTRAb
Number of patients 7427 67 19439 422
Mean  s.d. follow-up time (days) 351  45 297  86 350  46 321  74
At treatment initiation
Age (years); n (%)
5e<12 5888 (79.3) 49 (73.1) 15017 (77.3) 317 (75.1)
12e15 1539 (20.7) 18 (26.9) 4422 (22.7) 105 (24.6)
Male gender, n (%) 4370 (58.8) 34 (50.8) 10642 (54.8) 232 (55.0)
Receipt of social assistance; n (%) 2772 (37.3) 28 (41.8) 7266 (37.4) 124 (29.4)
Area of residence; n (%)c
Urban 5521 (74.3) 55 (82.1) 15402 (79.3) 327 (77.5)
Rural 1905 (25.7) 12 (17.9) 4033 (20.7) 95 (22.5)
Missing 1 0 4 0
Specialty of prescribing physician; n (%)
Family physician 5130 (69.0) 33 (49.2) 13339 (68.6) 202 (47.9)
Pediatrician 2062 (27.8) 29 (43.3) 5428 (27.9) 181 (42.9)
Respiratory physician 44 (0.6) 0 265 (1.4) 12 (2.8)
Other specialties 191 (2.6) 5 (7.5) 407 (2.1) 27 (6.4)
Median daily dose prescribed 1071 mg 5 mg 1000 mg 5 mg
In the year preceding treatment initiation
Average number of doses of inhaled SABAd per week; n (%)
3 6629 (89.3) 55 (82.1) 18033 (92.8) 379 (89.8)
>3e10 677 (9.1) 10 (14.9) 1189 (6.1) 37 (8.8)
>10 121 (1.6) 2 (3.0) 217 (1.1) 6 (1.4)
Oral SABAd (1 filled prescription); n (%) 418 (5.6) 5 (7.5) 895 (4.6) 29 (6.9)
LABAe (1 filled prescription); n (%) 5 (0.1) 1 (1.5) 26 (0.1) 4 (1.0)
Theophylline (1 filled prescription); n (%) 8 (0.1) 0 35 (0.2) 1 (0.2)
Short-course filled prescription of oral corticosteroids; n (%)
0 3351 (45.1) 27 (40.3) 19439 (100.0) 422 (100.0)
1 3601 (48.5) 30 (44.8)
2 475 (6.4) 10 (14.9)
Outpatient medical visit for asthma (1); n (%) 2996 (40.3) 53 (79.1) 19439 (100.0) 422(100.0)
EDf visit for asthma (1); n (%) 5574 (75.1) 34(50.8) 0 0
Hospitalization for asthma (1); n (%) 657 (8.9) 4(6.0) 0 0
Asthma exacerbations; n (%)
0 0 0 19439 (100.0) 422 (100.0)
1 6614 (89.0) 54 (80.6) 0 0
2 813 (11.0) 13 (19.4) 0 0
a ICS: Inhaled corticosteroids.
b LTRA: Leukotriene receptor antagonists.
c Measured in the 15 days preceding the index date.
d SABA: Short-acting beta-agonists.
e Long-acting beta-agonists.
f ED: Emergency department.
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tice setting is often questionable. Indeed, efficacy clinical
trials are performed under ideal settings, with carefully
selected patients, strict treatment protocols, and closemonitoring by the research team; poor adherence to drug
or follow-up visit is a common exclusion criteria. Conse-
quently, efficacy clinical trials minimize variability due to
physician prescription patterns and patient adherence to
Table 2 Crude Rate of Exacerbations for Children Treated with ICS or LTRA During Follow-up.
 1 exacerbation in the year
prior to treatment initiation
P-value No exacerbation
in the year prior
to treatment initiation
P-value
ICSa LTRAb ICSa LTRAb
Number of patients 7427 67 19439 422
Exacerbations
1 exacerbation; n (%) 1671 (22.5) 10 (14.9) 0.128 1535 (7.7) 14 (3.3) 0.001
Number of exacerbations 2252 12 1769 16
Rate of exacerbation/patient/year 0.32 0.22 0.09 0.04
Oral corticosteroids
1 filled prescription; n (%) 1222 (16.5) 5 (7.4) 0.068 1222 (6.3) 10 (2.4) 0.003
Number of filled prescriptions 1691 7 1464 13
Rate of oral corticosteroids/patient/year 0.24 0.13 0.08 0.04
EDc visit for asthma
1 EDc visit for asthma; n (%) 1158 (15.6) 7 (10.5) 0.389 708 (3.6) 7 (1.7) 0.037
Number EDc visit for asthma 1664 12 844 8
Rate of EDc visit for asthma/patient/year 0.23 0.22 0.05 0.02
Hospitalizations for asthma
1 hospitalizations for asthma; n (%) 167 (2.2) 3 (4.5) 0.175 85 (0.4) 1 (0.2) 0.340
Number of hospitalizations for asthma 191 3 88 1
Rate of hospitalizations for asthma/patient/year 0.03 0.06 0.005 0.003
a ICS: Inhaled corticosteroids.
b LTRA: Leukotriene-receptor antagonists.
c ED: Emergency department.
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patterns and patient adherence on the health outcomes is
thus best explored using data from a real-world setting.
Contrary to our initial hypothesis, patient adherence,
measured by the proportion of prescribed days covered,
was comparable between groups hovering around 66%. Of
interest, the proportion of days with supply prescribed,
reflecting prescription patterns and duration, is nearly
twice higher for LTRA compared to ICS, suggesting that
physician prescribe enough LTRA supply to last twice as
long as the ICS supply. The unusually high dose of ICS
hovering around 1000 mg/day and the higher rate of treat-
ment initiation during an exacerbation, suggest that ICS is
more frequently prescribed as a curative intermittent
treatment during an exacerbation than as a daily controller
medication, a pattern not found with LTRA. These findings
would suggest that a large proportion of the non-adherence
seen with the commonly employed “proportion of days
covered (PDC)” measure may not be due to patients’ non-
adherence to the prescribed medication, but rather to the
pattern of ICS prescription. This is in line with the findings
of recent US surveys which showed that only half of the
primary care physicians reported concordance with the
guidelines recommendations for the prescription of ICS
therapy for children with persistent asthma.34,35 The
resulting higher daily use of LTRA than ICS medications
could therefore explain, at least in part, the greater
reduction in exacerbations among children with asthma
treated by LTRA compared to ICS.The two-fold increased rate of asthma exacerbation
associated with ICS observed in this study also differ from
that reported in two similar other observational studies,
which themselves yielded inconsistent results.17,18 Stempel
and colleagues reported that children 4e17 years of age
treated with montelukast were 2.5 times more likely to
experience treatment failure (defined as asthma-related
hospitalizations, ED visits, oral corticosteroids use, or
switch/augmentation of index therapy) than those treated
with fluticasone (OR Z 2.55; 95% CI: 2.19e2.96).17 This
study did not include incident users of ICS or LTRA as we
did, but specifically required active ICS therapy in the year
in both groups before the index prescription; perhaps this
criteria led to the selection of patients that were particu-
larly responsive to their respective controlled medication.
Conversely, Allen-Ramey et al. showed that among children
2e14 years of age who were new users of ICS or LTRA, there
was no statistical difference between the montelukast and
fluticasone cohorts in the risk of rescue oral corticosteroids
(RR Z 1.02; 0.88e1.19). This result persisted in the
subgroup of children aged 6e14 years, more comparable to
our age group.18 No significant difference between the two
groups in the risk of asthma-related ED visits or hospitali-
zations were neither noted in the 6e14 years age group.
Those findings differ from ours, maybe because of differ-
ences in the baseline severity of patients between the two
studies. Indeed, in the Allen-Ramey study, there was
a significantly higher pre-index rate of oral corticosteroid
use among those who initiated fluticasone than among
Table 3 Crude and Adjusted Rate Ratios of Moderate or severe Asthma Exacerbations Comparing Children Treated with ICS
and LTRA During Follow-up.
1 exacerbation in the year
prior to treatment initiation
No exacerbation in the year prior
to treatment initiation
Crude RRa Adjusted RRa 95% CI Crude RRa Adjusted RRa 95% CI
ICSb vs. LTRAc 1.4 1.6 0.8e3.1 2.2 2.3 1.3e4.0
At treatment initiation
Age (<12 years vs.12e15 years) 1.2 1.2 1.0e1.4 1.1 1.1 1.0e1.2
Male vs. female 1.0 1.0 0.9e1.1 1.0 1.0 0.9e1.1
Area of residence (rural vs. urban) 0.9 0.9 0.8e1.1 1.0 1.1 0.9e1.2
Social assistance (yes vs. no) 1.1 1.1 1.0e1.2 1.1 1.1 1.0e1.2
Specialty of prescribing physician
Family physician Reference Reference
Pediatrician 1.3 1.2 1.1e1.4 1.2 1.2 1.1e1.3
Respiratory physician 0.9 0.8 0.4e1.7 0.5 0.5 0.3e1.0
Other specialties 1.5 1.4 1.1e1.8 0.9 1.0 0.7e1.4
In the year prior to treatment initiation
Number of doses of SABAd/week
0e3 Reference Reference
>3-10 1.8 1.8 1.5e2.0 1.7 1.7 1.4e2.1
>10 2.6 2.7 2.1e3.5 2.4 2.6 1.8e3.6
Oral SABAd (yes vs. no) 1.4 1.3 1.1e1.6 1.1 1.1 0.8e1.4
LABAe (yes vs. no) 0.6 0.5 0.1e5.6 0.4 0.4 0.0e3.8
a RR: Rate ratio; adjusted for age, sex, area of residence, social assistance, specialty of prescribing physician, average number of
doses of inhaled short-acting beta2-agonists (SABA) per week, oral SABA and inhaled long-acting beta2-agonists (LABA).
b ICS: Inhaled corticosteroids.
c LTRA: Leukotriene-receptor antagonists.
d SABA: Short-acting beta-agonists.
e LABA: Long-acting beta-agonists.
852 L. Blais et al.those who initiated montelukast, contrarily to our study. Of
interest, none of these studies compared the proportion of
days covered by the prescribed therapy, patient’s adher-
ence to the prescribed therapy and the usage of ICS and
LTRA, which are important elements to consider when
examining drug effectiveness.
Our study has several strengths. First, it is a population-
based effectiveness study, representative of real-world
clinical practice. Second, our data were obtained from
a validated healthcare database providing detailed infor-
mation on prescribed medications recorded prospectively,
thus excluding the possibility of recall bias. Third, we used
established and objective markers of moderate and severe
asthma exacerbations.36e38 Finally, the large sample size
provided precise estimates of association.
We acknowledge the following limitations. First and
foremost, as for any non-randomized population-based
study, it is not possible to control treatment assignment
which could potentially lead to systematic differences
between the two study groups, a phenomenon called con-
founding by indication. In other words, ICS may have been
used for children with more severe asthma than those
treated with LTRA. We attempted to minimize such bias by
stratifying all the analyses for the occurrence or not ofa moderate or severe asthma exacerbation in the year
before treatment initiation. Although the stratification led
to comparable treatment groups for most variables in the
strata with no prior exacerbation, we cannot rule out
imbalances in other unmeasured variables known to be
associated with asthma morbidity, such as ethnicity or
environmental factors (aeroallergens).39,40 In the strata
with prior exacerbations, several group imbalances
remained that could have masked important group differ-
ences in health outcomes. Other clinical markers of disease
severity at the baseline such as lung function or asthma
symptoms were not provided by administrative databases
and thus could not be used for a more precise assessment of
asthma severity. The data retrieved from the Medical and
Prescription databases were validated in adults and not in
children. Adherence to study medications was based on
dispensed prescriptions and not the actual use of medica-
tions; while one cannot prove intake from dispensed
medication, intake cannot take place without first
dispensing. The use of administrative databases does not
allow determining whether patients have filled their new
prescription, which may have resulted in an underestima-
tion of the number of new prescriptions and allowed refills
as only prescriptions that reach the pharmacy are
Table 4 Treatment Adherence to ICS and LTRA in the Year Following Treatment Initiation.
 1 exacerbation prior to treatment initiation No exacerbation prior to treatment initiation
ICSa LTRAb ICSa LTRAb
Number of patients 7427 67 19439 422
Proportion of days with supply prescribed
Mean percentage (s d) 32.8 (30.1) 55.9 (35.9)c 34.0 (30.9) 51.9 (35.1)c
Proportion of Prescribed Days Covered (PPDC )
Mean percentage (s d) 68.0 (33.0) 64.7 (29.3)d 63.9 (34.4) 62.7 (33.5)d
Proportion of Days Covered (PDC )
Mean percentage (s d) 15.1 (12.2) 33.3 (28.3)c 14.2 (11.6) 29.4 (28.7)c
Number of prescriptions dispensed per year
Mean number (s d) 4.4 (5.7) 7.9 (11.3)c 4.4 (5.2) 6.8 (8.1)c
DEFINITIONS:Proportion of days with supply prescribed Z Total days’ supply prescribed (i.e. the sum of the duration of all new
prescriptions plus allowed refills over the follow-up period)/Duration of follow-up: reflects prescription patterns.Proportion of
Prescribed Days Covered (PPDC) Z Total days’ supply dispensed over the follow-up period/Total days’ supply prescribed: reflects
patients’ adherence to prescribed therapy.Proportion of Days Covered (PDC) Z Total days’ supply dispensed during follow-up period/
Duration of Follow-up: reflects usage of medications (both patient and physician behaviour).
a ICS: Inhaled corticosteroids.
b LTRA: Leukotriene receptor antagonists.
c All p-values < 0.001 for the ICS/LTRA comparison with a t-test (PDSP, PDC and number of prescriptions per year).
d P-value Z 0.184 for the ICS/LTRA comparison with a t-test (PPDC).
Inhaled corticosteroids vs. leukotriene-receptor antagonists 853accounted for in the database. Our new measure of patient
adherence was based on the total days’ supply prescribed,
i.e. the sum of the duration of all prescriptions e new and
allowed refills from all physicians consulted during the
follow-up period. Thus, it doesn’t take into account the
variation in the doses that may have occurred between two
refills based on action plans for example. So, it is possible
that adherence would be underestimated particularly in
the case of ICS. Finally, the absence of a significant result in
the group of patients with a previous exacerbation might be
due to reduced power driven by the small number of
patients treated with LTRA.
With regards to generalizability, our population is mostly
representative of children whose parents are from the
lower to middle class population of Quebec. However, the
free healthcare and access to medication in children of
Quebec may make the impact of social class less important
than in other health care systems.
In conclusion, this effectiveness study of real life drug
utilisation patterns in the Canadian setting revealed that the
risk of asthma exacerbations was two-fold higher in children
prescribed ICS compared to LTRA in children without exacer-
bations requiring health care resources in the year prior to
treatment initiation; with no difference in children with prior
exacerbations. Higher proportion of days with a supply
prescribed and of days of use of LTRA compared to ICS in light
of similar patient’s adherence, suggest that the prescribing of
ICS as an intermittent rather than a daily controller explain in
part our findings. Yet, confounding by indication cannot be
firmly ruled out. Our study demonstrates the importance of
considering the prescribing patterns while measuring
patients’ adherence with prescription refills recorded in
administrative databases.Ethics statement
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